UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other
Jurisdiction of Incorporation or Organization) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including
area code: (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
A total of 34,581,020 shares of common stock of Collegium Pharmaceutical, Inc. (the “Company”) were entitled to vote as of March 31, 2023, the record date for the Annual Meeting, of which 30,815,695 were present in person or by proxy at the Annual Meeting. The following is a summary of the final voting results for each matter presented to shareholders.
PROPOSAL 1:
Election of nine Directors to hold office until the 2024 Annual Meeting of Shareholders.
Nominee | For | Against | Abstentions | Broker Non-Votes | ||||||||||||
Rita Balice-Gordon | 28,110,968 | 228,126 | 20,717 | 2,455,884 | ||||||||||||
Garen Bohlin | 28,254,994 | 83,040 | 21,777 | 2,455,884 | ||||||||||||
Joseph Ciaffoni | 28,252,708 | 86,385 | 20,718 | 2,455,884 | ||||||||||||
John Fallon | 25,876,429 | 2,462,321 | 21,061 | 2,455,884 | ||||||||||||
John Freund | 28,244,410 | 94,340 | 21,061 | 2,455,884 | ||||||||||||
Michael Heffernan | 26,667,450 | 1,671,643 | 20,718 | 2,455,884 | ||||||||||||
Neil McFarlane | 28,255,598 | 83,495 | 20,718 | 2,455,884 | ||||||||||||
Gwen Melincoff | 27,982,535 | 353,536 | 23,740 | 2,455,884 | ||||||||||||
Gino Santini | 28,128,667 | 210,074 | 21,070 | 2,455,884 |
Each of Rita Balice-Gordon, Garen Bohlin, Joseph Ciaffoni, John Fallon, John Freund, Michael Heffernan, Neil F. McFarlane, Gwen Melincoff, and Gino Santini was re-elected by the Company’s shareholders as Directors to hold office until the 2024 Annual Meeting of Shareholders.
PROPOSAL 2:
Approval of, on an advisory basis, the compensation of the Company’s named executive officers.
For | Against | Abstentions | Broker Non-Votes | |||||||||||
27,953,926 | 315,383 | 90,502 | 2,455,884 |
On an advisory basis, the Company’s shareholders approved the compensation of the Company’s named executive officers.
PROPOSAL 3:
Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
For | Against | Abstentions | Broker Non-Votes | |||||||||||
30,742,534 | 44,006 | 29,155 | 0 |
Proposal 3 was approved by the Company’s shareholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 19, 2023 | Collegium Pharmaceutical, Inc. | |
By: | /s/ Colleen Tupper | |
Name: Colleen Tupper | ||
Title: Executive Vice President and Chief Financial Officer |